Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
SUMMARY: Aim: Plasma adiponectin levels are well associated with metabolic syndrome. However, the relationship between hypertension and plasma adiponectin levels is not clear. Also, there is not enough data about the effects of different antihypertensive regimens on plasma adiponectin levels. Methods: Ninety‐six hypertensive patients (48 male, 48 female) who fulfil the diagnostic criteria of metabolic syndrome were enrolled. Patients were treated for 3 months with metoprolol (n = 18, 100 mg/day), amlodipine (n = 20, 10 mg/day), doxazosin (n = 18, 4 mg/day), ramipril (n = 20, 5 mg/day) and valsartan (n = 20, 80 mg/day). Blood biochemistry and plasma adiponectin concentrations were measured both before and after the study. Insulin resistance was measured by homeostasis assessment index (HOMA). Results: Plasma adiponectin levels were correlated with the total cholesterol (r = −0.244, P = 0.017), triglyceride (r = −0.306, P = 0.002), high‐density lipoprotein‐cholesterol (r = 0.286, P = 0.005), body mass index (r = −374, P < 0.001), systolic (r = −502, P < 0.001) and diastolic blood pressures (r = −235, P = 0.021). The independent predictors of plasma adiponectin levels were HOMA (β = −0.199, P = 0.02), body mass index (β = −0.313, P < 0.001) and sytolic blood pressures (β = −0.483, P < 0.001). Ramipril and valsartan increased the plasma adiponectin levels significantly higher than the other regimens (P < 0.05 for both) while metoprolol did not make a significant effect. Conclusion: According to the results, plasma adiponectin levels are associated with the arterial blood pressures, body fat content and the lipid parameters in hypertensive patients with metabolic syndrome. The effects of antihypertensive drugs on plasma adiponectin levels are parallel to their effects on blood pressures and insulin sensitivities. The different effects of several regimens on plasma adiponectin levels and insulin sensitivities may account for the diversity of the cardiovascular outcomes in patients with hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., & Tataranni, P. A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7463 · Cited by 3,541
Yang, W.-S., Lee, W.-J., Funahashi, T., Tanaka, S., Matsuzawa, Y., Chao, C.-L., Chen, C.-L., Tai, T.-Y., & Chuang, L.-M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3815 · Cited by 1,181
Wing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130
Effect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737
Insulin Resistance/Compensatory Hyperinsulinemia, Essential Hypertension, and Cardiovascular Disease
Reaven, G. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030087 · Cited by 284 · cited 1×
“Although hypertension is a component of metabolic syndrome, it has been shown that insulin resistant is not present in every hypertensive patient.(30) Previously we reported that young active men with new onset uncomplicated hypertension, have no significant change in plasma adiponectin levels and there were no correl…”
Background
Cited by
Pharmacological and Clinical Aspects of Heme Oxygenase
Abraham, N. G., & Kappas, A. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07104 · Cited by 1,115
Obesity, Adipose Tissue and Vascular Dysfunction
Koenen, M., Hill, M. A., Cohen, P., & Sowers, J. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318093 · Cited by 904
Li, M., Kim, D. H., Tsenovoy, P. L., Peterson, S. J., Rezzani, R., Rodella, L. F., Aronow, W. S., Ikehara, S., & Abraham, N. G. (2008) · Diabetes · doi:10.2337/db07-1764 · Cited by 311
Adiponectin and cardiovascular health: an update
Hui, X., Lam, K. S., Vanhoutte, P. M., & Xu, A. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01395.x · Cited by 286
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Polyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 277
Metadata
- Authors
- YILMAZ, M. I., SONMEZ, A., CAGLAR, K., CELIK, T., YENICESU, M., EYILETEN, T., ACIKEL, C., OGUZ, Y., YAVUZ, I., & VURAL, A.
- Venue
- Nephrology
- Publisher
- Wiley
- Published
- 2007-02-06
- Volume
- 12
- Issue
- 2
- Pages
- 147-153
- ISSN
- 1320-5358 (ISSN-L)
- 1440-1797
- OpenAlex
- W1966997395
- Cited by
- 111
- References
- 7
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.